Our Approach

Through our research and partnerships, we are helping to shape the real-world evidence industry and advance the field of oncology.

Our collaborations are leading industry to advance the treatment landscape, reimagine the drug development life cycle, and accelerate value-based care models.

Our Research and Publications

Discover more about how our work with the FDA, industry and academia helps to ensure that everyone touched by cancer is given a clear path to the right care.

ESMO IO 2019: Cost of Adverse Events (AEs) With Second-line (2L) Immuno-Oncology Agents (IO) and Chemotherapy (CHEMO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) in the Real World

In collaboration with Bristol-Myers Squibb, COTA investigated the incidence and cost of adverse events among aNSCLC patients treated with 2L immuno-oncology agents as compared to 2L chemotherapy, finding lower cost among patients treated with IO.
READ MORE

ASH 2019: Chromosome 1q Amplification Is Associated with a History of Prior Malignancies Among Patients Newly Diagnosed with Multiple Myeloma

Using COTA RWD, our research showed that newly diagnosed multiple myeloma patients with histories of prostate cancer and those with two or more prior malignancies were more likely to have amp(1q), a poor prognostic marker in MM.
READ MORE

An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer

COTA was one of six organizations to participate in a collaboration to explore the consistency of real-world endpoints across diverse datasets and the potential validity of RWD to support regulatory and payer decision making.
READ MORE

ASCO 2019: Real-World Characterization of Advanced/Metastatic Non-Small Cell Lung Cancer Patients with Rapid Disease Progression

In collaboration with Eli Lilly, COTA characterized patients with non-small cell lung cancer whose disease progresses within <12 weeks of diagnosis, a notable poor prognosis cohort.
READ MORE

ASCO 2019: Rates of Genotyping for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair in Metastatic Colon Cancer Patients: Gaps and Implications.

In collaboration with Guardant Health, COTA investigated the molecular testing rates of patients with metastatic colon cancer and found that <25% of our cohort received guideline recommended genotyping.
READ MORE

ASMR 2018: Immunotherapy or Targeted Therapy as Initial Therapy for Advanced Melanoma: a Real World Analysis

In collaboration with Bristol-Myers Squibb, COTA explored the treatment landscape in metastatic melanoma and found that among patients with BRAF V-600 mutation, initial treatment with immunotherapy may improve overall survival as compared to targeted therapy.
READ MORE

COTA in the News

Real-World Data Reveals Quality Gaps in Routine Cancer Care

Real-World Data Reveals Quality Gaps in Routine Cancer Care

A recent collaboration between COTA and Guardant Health found quality gaps in routine cancer care. In this article, members of COTA’s medical team detail the study, including key takeaways & future directions.
READ MORE
FierceHealthcare names COTA as one of its 2020 “Fierce 15” Companies

FierceHealthcare names COTA as one of its 2020 “Fierce 15” Companies

COTA honored as one of the 15 most promising US companies trying to change the world by changing the healthcare industry.
READ MORE
A study showed RWE can replicate only 15% of RCTs – is this accurate?

A study showed RWE can replicate only 15% of RCTs – is this accurate?

COTA’s medical team discusses the most promising use cases of RWE in clinical research.
READ MORE
Real-world evidence at a glance: How a collaboration of “frenemies” produced common definitions for real-world endpoints

Real-world evidence at a glance: How a collaboration of “frenemies” produced common definitions for real-world endpoints

Highlights of the Friends of Cancer Research pilot project studying RWE endpoints.
READ MORE
RWE to Supplement RCTs: FDA Projects Continue

RWE to Supplement RCTs: FDA Projects Continue

COTA CEO Mike Doyle and CMO Andrew Norden discuss the role of RWE in randomized control trials and how it has the potential to accelerate the pace of clinical development. “The goal here isn’t to replace a trial, it’s to separate existing trials and complement existing trials.”
READ MORE
FDA Leverages Private Sector Technology Based Tools In Its Embrace Of Real World Evidence

FDA Leverages Private Sector Technology Based Tools In Its Embrace Of Real World Evidence

Following decades of near total reliance on randomized clinical trial data, the U.S. Food & Drug Administration (with a helpful nudge from the Congress) is accessing private sector technology based tools as a means of incorporating real world data (RWD) and evidence (RWE) into its drug approval, label expansion and regulatory oversight tasks.
READ MORE

Press Releases

COTA Brings on Innovative Veteran CEO to Drive Next Phase of Growth and Delivery of Breakthrough Technology and Insights

READ MORE

COTA Increases Breakthrough Capability, adds Chief Technology Officer

READ MORE

Our collective responsibility
to apply real-world evidence

FDA and COTA recently finalized a research collaboration agreement. Research efforts are underway across tumor types to assess the utility of RWE in drug development for high unmet need populations and in accelerating clinical trials.

Friends of Cancer Research and COTA partnered in a pilot study of immune checkpoint inhibitors approved for non-small cell lung cancer to define a standard data framework and to assess correlation between real-world endpoints and overall survival.

Let’s work together to transform cancer care.

CONTACT US

Bringing clarity
to cancer

We are working to ensure that everyone touched by cancer has a clear path to the right care.